Delivery Represents Approximately $22 Million of Revenue Generated
During 1Q 2007
ROCKVILLE, Md.--(BUSINESS WIRE)--Feb. 23, 2007--Emergent
BioSolutions Inc. (NYSE: EBS) announced that yesterday it delivered
just under one million doses of BioThrax(R) (Anthrax Vaccine
Adsorbed), the only FDA licensed anthrax vaccine, to the Department of
Health and Human Services (HHS) for placement into the nation's
strategic national stockpile (SNS). This delivery represents revenue
of approximately $22 million generated during 1Q 2007. These doses
were provided to HHS ahead of schedule under a May 2006 modified
contract that required the company to deliver five million doses to
HHS before May 31, 2007. Since May 2005, the company has supplied 10
million doses of BioThrax to HHS for inclusion in the SNS.
"I am very proud of the fact that we have fulfilled, ahead of
schedule, our commitment to deliver an additional 5 million doses of
BioThrax to HHS for placement into the SNS," stated Fuad El-Hibri,
chairman and chief executive officer of Emergent BioSolutions. "HHS
has to date ordered and received from us 10 million doses of BioThrax
for the SNS. Having fully satisfied our existing contractual
obligations to HHS, we are now prepared to assist the agency in
fulfilling its previously announced requirement for 75 million doses
of anthrax vaccine."
The SNS, which is administered by the U.S. Centers for Disease
Control and Prevention, is a national repository of medical assets and
countermeasures designed to provide state and local public health
agencies with medical supplies needed to treat those affected by
terrorist attacks, natural disasters, industrial accidents and other
public health emergencies, such as a flu epidemic.
About Emergent BioSolutions Inc.
Emergent BioSolutions Inc. is a biopharmaceutical company focused
on the development, manufacture and commercialization of
immunobiotics, such as vaccines and therapeutics that induce or assist
the body's immune system to prevent or treat disease. The company's
biodefense business is focused on developing and commercializing
immunobiotics for use against biological agents that are potential
weapons of bioterrorism. The company's commercial business is focused
on developing immunobiotics for use against infectious diseases with
significant unmet or underserved medical needs. More information on
the company is available at www.emergentbiosolutions.com.
Safe Harbor Statement
This press release includes forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Any
statements, other than statements of historical fact, our strategy,
future operations, future financial position, future revenues,
projected costs, prospects, plans and objectives of management and any
other statements containing the words "believes", "expects",
"anticipates", "plans", "estimates" and similar expressions are
forward-looking statements. There are a number of important factors
that could cause the company's actual results to differ materially
from those indicated by such forward-looking statements, including our
performance under existing BioThrax(R) sales contracts with the U.S.
government, including the timing of deliveries under these contracts;
our ability to obtain new BioThrax sales contracts with the U.S.
government; our plans for future sales of BioThrax; our plans to
pursue label expansions and improvements for BioThrax; our plans to
expand our manufacturing facilities and capabilities; the rate and
degree of market acceptance and clinical utility of our products; our
ongoing and planned development programs, preclinical studies and
clinical trials; our ability to identify and acquire or in license
products and product candidates that satisfy our selection criteria;
the potential benefits of our existing collaboration agreements and
our ability to enter into selective additional collaboration
arrangements; the timing of and our ability to obtain and maintain
regulatory approvals for our product candidates; our
commercialization, marketing and manufacturing capabilities and
strategy; our intellectual property portfolio; our estimates regarding
expenses, future revenue, capital requirements and needs for
additional financing; and other factors identified in the company's
Registration Statement on Form S-1 and subsequent reports filed with
the SEC. The company disclaims any intention or obligation to update
any forward-looking statements as a result of developments occurring
after the date of this press release.
CONTACT: Emergent BioSolutions Inc.
Robert G. Burrows, 301-795-1877
Vice President, Corporate Communications
SOURCE: Emergent BioSolutions Inc.